Literature DB >> 9376279

No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.

S M Edwards1, D P Dearnaley, A Ardern-Jones, R A Hamoudi, D F Easton, D Ford, R Shearer, A Dowe, R A Eeles.   

Abstract

There is evidence that predisposition to cancer has a genetic component. Genetic models have suggested that there is at least one highly penetrant gene predisposing to this disease. The oncogene MXI1 on chromosome band 10q24-25 is mutated in a proportion of prostate tumours and loss of heterozygosity occurs at this site, suggesting the location of a tumour suppressor in this region. To investigate the possibility that MXI1 may be involved in inherited susceptibility to prostate cancer, we have sequenced the HLH and ZIP regions of the gene in 38 families with either three cases of prostate cancer or two affected siblings both diagnosed below the age of 67 years. These are the areas within which mutations have been described in some sporadic prostate cancers. No mutations were found in these two important coding regions and we therefore conclude that MXI1 does not make a major contribution to prostate cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376279      PMCID: PMC2228090          DOI: 10.1038/bjc.1997.498

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription.

Authors:  G J Kato; J Barrett; M Villa-Garcia; C V Dang
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 2.  The contribution of inherited predisposition to cancer incidence.

Authors:  D Easton; J Peto
Journal:  Cancer Surv       Date:  1990

3.  Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.

Authors:  J R Smith; D Freije; J D Carpten; H Grönberg; J Xu; S D Isaacs; M J Brownstein; G S Bova; H Guo; P Bujnovszky; D R Nusskern; J E Damber; A Bergh; M Emanuelsson; O P Kallioniemi; J Walker-Daniels; J E Bailey-Wilson; T H Beaty; D A Meyers; P C Walsh; F S Collins; J M Trent; W B Isaacs
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.

Authors:  R Buttyan; I S Sawczuk; M C Benson; J D Siegal; C A Olsson
Journal:  Prostate       Date:  1987       Impact factor: 4.104

6.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.

Authors:  C Murre; P S McCaw; D Baltimore
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

7.  Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants.

Authors:  L M Kunkel; K D Smith; S H Boyer; D S Borgaonkar; S S Wachtel; O J Miller; W R Breg; H W Jones; J M Rary
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

8.  Mendelian inheritance of familial prostate cancer.

Authors:  B S Carter; T H Beaty; G D Steinberg; B Childs; P C Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Family history and the risk of prostate cancer.

Authors:  G D Steinberg; B S Carter; T H Beaty; B Childs; P C Walsh
Journal:  Prostate       Date:  1990       Impact factor: 4.104

10.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.

Authors:  A S Zervos; J Gyuris; R Brent
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

View more
  9 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 2.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

3.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

Authors:  Stephen M Edwards; Zsofia Kote-Jarai; Julia Meitz; Rifat Hamoudi; Questa Hope; Peter Osin; Rachel Jackson; Christine Southgate; Rashmi Singh; Alison Falconer; David P Dearnaley; Audrey Ardern-Jones; Annette Murkin; Anna Dowe; Jo Kelly; Sue Williams; Richard Oram; Margaret Stevens; Dawn M Teare; Bruce A J Ponder; Simon A Gayther; Doug F Easton; Rosalind A Eeles
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

4.  Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Authors:  S M Edwards; D G R Evans; Q Hope; A R Norman; Y Barbachano; S Bullock; Z Kote-Jarai; J Meitz; A Falconer; P Osin; C Fisher; M Guy; S G Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; D P Dearnaley; A T Ardern-Jones; E C Page; D F Easton; R A Eeles
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

5.  Germline BRCA1 mutations increase prostate cancer risk.

Authors:  D Leongamornlert; N Mahmud; M Tymrakiewicz; E Saunders; T Dadaev; E Castro; C Goh; K Govindasami; M Guy; L O'Brien; E Sawyer; A Hall; R Wilkinson; D Easton; D Goldgar; R Eeles; Z Kote-Jarai
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

6.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Authors:  Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles
Journal:  Br J Cancer       Date:  2011-09-27       Impact factor: 7.640

7.  HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease.

Authors:  J C Meitz; S M Edwards; D F Easton; A Murkin; A Ardern-Jones; R A Jackson; S Williams; D P Dearnaley; M R Stratton; R S Houlston; R A Eeles
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

8.  Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.

Authors:  D Leongamornlert; E Saunders; T Dadaev; M Tymrakiewicz; C Goh; S Jugurnauth-Little; I Kozarewa; K Fenwick; I Assiotis; D Barrowdale; K Govindasami; M Guy; E Sawyer; R Wilkinson; A C Antoniou; R Eeles; Z Kote-Jarai
Journal:  Br J Cancer       Date:  2014-02-20       Impact factor: 7.640

9.  ATM polymorphisms as risk factors for prostate cancer development.

Authors:  S Angèle; A Falconer; S M Edwards; T Dörk; M Bremer; N Moullan; B Chapot; K Muir; R Houlston; A R Norman; S Bullock; Q Hope; J Meitz; D Dearnaley; A Dowe; C Southgate; A Ardern-Jones; D F Easton; R A Eeles; J Hall
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.